The creation of a Precision Medicine Catapult national network based in Cambridge has been hailed by Dr Eliot Forster, Executive Chair of MedCity, as a boost to the UK’s health and economy that will help deliver the right treatment at the right time to the right patient

The Precision Medicine Catapult network will promote the UK as a leader in a field of medicine that aims to ensure each patient gets the most appropriate treatment based on an understanding of their genomic makeup.

Dr Forster says:

“This is a great move to put the UK at the forefront of this burgeoning area of science. It will attract significant interest and new investment. Individualisation is the future of healthcare – delivering the right treatment at the right time to the right patient means better health outcomes, a more cost-efficient health service and the faster development of new therapies.

“The new catapult will give a real boost to our capacity to commercialise our innovative research in precision medicine, with the consequence of far-reaching health and economic benefits. This is a substantial and very welcome addition to the UK’s rich life sciences ecosystem.”

The appointment of John McKinley as CEO has also been announced today.

See the full announcement from the Chancellor of the Exchequer here: